Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3.

Nuclear localized HER family receptor tyrosine kinases (RTKs) have been observed in primary tumor specimens and cancer cell lines for nearly two decades. Inside the nucleus, HER family members (EGFR, HER2, and HER3) have been shown to function as co-transcriptional activators for various cancer-prom...

Full description

Bibliographic Details
Main Authors:	Toni M Brand, Mari Iida, Neha Luthar, Matthew J Wleklinski, Megan M Starr, Deric L Wheeler
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3738522?pdf=render

Similar Items

Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
by: Hwang-Phill Kim, et al.
Published: (2009-01-01)

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy
by: Carla De Giovanni, et al.
Published: (2021-07-01)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
by: Ilana Schlam, et al.
Published: (2021-05-01)

Tyrosine Kinase Inhibitors in the Combination Therapy of HER2 Positive Breast Cancer
by: Xue Yang MSc, et al.
Published: (2020-10-01)

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.
by: Anthony Kong, et al.
Published: (2008-08-01)

HER2-targeted hybrid peptide that blocks HER2 tyrosine kinase disintegrates cancer cell membrane and inhibits tumor growth in vivo
by: Kawamoto, Megumi
Published: (2014)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
by: Nathan Griffin, et al.
Published: (2020-09-01)

Tyrosine Kinase Inhibitors Are Promising Therapeutic Tools for Cats with HER2-Positive Mammary Carcinoma
by: Andreia Gameiro, et al.
Published: (2021-03-01)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
by: Martina S. J. McDermott, et al.
Published: (2019-02-01)

Laboratory and clinical studies of the dual EGFR/HER2 tyrosine kinase inhibitor lapatinib in breast cancer
by: Leary, Alexandra
Published: (2011)

An optical proteomic profile of the HER2 family in breast tumours and the effect of exposure to tyrosine kinase inhibitors
by: Patel, Gargi
Published: (2013)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
by: Sun Y, et al.
Published: (2021-09-01)

Nuclear factor erythroid 2-related factor 2 modulates HER4 receptor in ovarian cancer cells to influence their sensitivity to tyrosine kinase inhibitors
by: Ibrahim H. Kankia, et al.
Published: (2021-04-01)

Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
by: Mari Iida, et al.
Published: (2013-10-01)

Optimization of substituted 6-salicyl-4-anilinoquinazoline derivatives as dual EGFR/HER2 tyrosine kinase inhibitors.
by: Dong-Dong Li, et al.
Published: (2013-01-01)

Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy
by: Robert Torka, et al.
Published: (2014-04-01)

A mathematical model separates quantitatively the cytostatic and cytotoxic effects of a HER2 tyrosine kinase inhibitor
by: Wang Shizhen, et al.
Published: (2007-04-01)

Modulation of DNA strand break induction and repair by tyrosine kinase inhibitors targeted against EGFR and HER2
by: Bhosle, J.
Published: (2012)

Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
by: Hamilton Erika, et al.
Published: (2012-02-01)

Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
by: Richard L. Schroeder, et al.
Published: (2014-09-01)

Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model
by: Collantes Maria, et al.
Published: (2010-05-01)

Studies on the function and subcellular localisation of the c-erbB-4/HER-4 tyrosine kinase growth factor receptor
by: Levinson, Neil Robert
Published: (2002)

The C-Terminal Transactivation Domain of STAT1 Has a Gene-Specific Role in Transactivation and Cofactor Recruitment
by: Matthias Parrini, et al.
Published: (2018-12-01)

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer
by: Schwill, Martin, et al.
Published: (2020)

Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor
by: Donatella Romaniello, et al.
Published: (2020-08-01)

PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations
by: Qiuju Dong, et al.
Published: (2019-04-01)

SATB1-Mediated Upregulation of the Oncogenic Receptor Tyrosine Kinase HER3 Antagonizes MET Inhibition in Gastric Cancer Cells
by: Robert Jenke, et al.
Published: (2021-12-01)

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
by: Marie-Anne Goyette, et al.
Published: (2018-05-01)

Nuclear Functions of the Tyrosine Kinase Src
by: Giulia Bagnato, et al.
Published: (2020-04-01)

Transactivation of ErbB Family of Receptor Tyrosine Kinases Is Inhibited by Angiotensin-(1-7) via Its Mas Receptor.
by: Saghir Akhtar, et al.
Published: (2015-01-01)

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and <i>HER2</i>-Mutated Breast Cancer
by: Denis M. Collins, et al.
Published: (2019-05-01)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
by: Maria Antonietta Lucci, et al.
Published: (2010-01-01)

Araguspongine C Induces Autophagic Death in Breast Cancer Cells through Suppression of c-Met and HER2 Receptor Tyrosine Kinase Signaling
by: Mohamed R. Akl, et al.
Published: (2015-01-01)

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers
by: Avisek Majumder, et al.
Published: (2021-04-01)

Targeting HER2 in Nuclear Medicine for Imaging and Therapy
by: Adriana V. F. Massicano PhD, et al.
Published: (2018-01-01)

Biological effects of anti-peptide antibodies against the her-2/neu receptor tyrosine kinase : implications for therapy of human breast cancer /
by: Woodbine, Donna-Beth
Published: (1997)

The efficacy and safety of Tyrosine kinase inhibitors in HER-2 positive breast cancer with brain metastases: a systematic review and meta analysis
by: Y. Yu, et al.
Published: (2021-04-01)

Her
by: Kim, Sung Hwan, 1975-
Published: (2012)

Galina Ustvolskaya : her heritage and her voice
by: Dullaghan, Andre
Published: (2000)

SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1
by: James W Peacock, et al.
Published: (2018-02-01)